ARID2 and plasma cell myeloma: In contrast, POM can suppress the c-MYC gene via proteasome-dependent degradation of AT-rich interaction domain 2 (ARID2), which is not a target molecule of LEN, suggesting that POM might be effective for a part of LEN-resistant myeloma cells [22].